A new strategy to prevent anthracycline-induced cardiotoxicity while improving anti-cancer activity [ 2013 - 2016 ]

Research Grant

Researchers: Dr Suzanne Cutts (Principal investigator) ,  A/Pr Salvatore Pepe

Brief description The anthracycline-based drugs such as doxorubicin currently used for cancer treatment have a major side effect in that they induce heart damage. We have shown that doxorubicin action can be modified to result in greater tumour cell kill, but also with reduced death of cardiac cells. We now aim to develop a molecular understanding of this process in order to allow better design of chemotherapy regimes that include the anthracyclines.

Funding Amount $AUD 318,034.66

Funding Scheme Project Grants

Notes Standard Project Grant